Article

Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options.

Department of Neurology, University of Ulm, Ulm, Germany.
European Journal of Neurology (Impact Factor: 3.85). 04/2009; 16(3):297-309. DOI: 10.1111/j.1468-1331.2008.02513.x
Source: PubMed

ABSTRACT Tauopathies with parkinsonism represent a spectrum of disease entities unified by the pathologic accumulation of hyperphosphorylated tau protein fragments within the central nervous system. These pathologic characteristics suggest shared pathogenetic pathways and possible molecular targets for disease-modifying therapeutic interventions. Natural history studies, for instance, in progressive supranuclear palsy, frontotemporal dementia with parkinsonism linked to chromosome 17, corticobasal degeneration, and Niemann-Pick disease type C as well as in amyotrophic lateral sclerosis/Parkinson-dementia complex permit clinical characterization of the disease phenotypes and are crucial to the development and validation of biological markers for differential diagnostics and disease monitoring, for example, by use of neuroimaging or proteomic approaches. The wide pathologic and clinical spectrum of the tauopathies with parkinsonism is reviewed in this article, and perspectives on future advances in the understanding of the pathogenesis are given, together with potential therapeutic strategies.

Download full-text

Full-text

Available from: Zygmunt Jamrozik, Jun 16, 2015
0 Followers
 · 
128 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The paper reviews of all of the current evidence on Theory of Mind (ToM) abilities in patients with neurodegenerative diseases. ToM refers to the abilities to attribute mental states to others. Two neural systems are involved in processing other people's beliefs and intentions (cognitive component) and others' emotions and feelings (affective component). We hypothesize that patients with different neurodegenerative diseases may present different patterns of ToM deficits on the basis of how different neuropathological processes affect the neural bases of ToM components during the progression of a disease. The studies we reviewed provided evidence of a deficit of the cognitive ToM component in cortical (Alzheimer's disease and frontotemporal dementia) and frontal-subcortical (amyotrophic lateral sclerosis and basal ganglia disorders) neurodegenerative diseases. As regards the affective ToM component, it resulted markedly impaired in frontotemporal dementia; it also resulted that performances in tasks assessing this process are heterogeneous in Parkinson's disease and amyotrophic lateral sclerosis. The findings presented support the opportunity to introduce validated ToM tasks in the neuropsychological assessment of neurodegenerative diseases.
    Neuroscience & Biobehavioral Reviews 07/2012; 36(9):2147-64. DOI:10.1016/j.neubiorev.2012.07.004 · 10.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The conserved Hsp90 chaperone is an ATP-controlled machine that assists the folding and controls the stability of select proteins. Emerging data explain how Hsp90 achieves client specificity and its role in the cellular chaperone cascade. Interestingly, Hsp90 has an extended substrate binding interface that crosses domain boundaries, exhibiting specificity for proteins with hydrophobic residues spread over a large area regardless of whether they are disordered, partly folded, or even folded. This specificity principle ensures that clients preferentially bind to Hsp70 early on in the folding path, but downstream folding intermediates bind Hsp90. Discussed here, the emerging model is that the Hsp90 ATPase does not modulate client affinity but instead controls substrate influx from Hsp70. Copyright © 2014 Elsevier Ltd. All rights reserved.
    Trends in Biochemical Sciences 01/2015; DOI:10.1016/j.tibs.2014.12.002 · 13.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Proteins aggregate in several slowly progressive neurodegenerative diseases called "proteinopathies." Studies with cell cultures and transgenic mice overexpressing mutated proteins suggested that aggregates of one protein induced misfolding and aggregation of other proteins as well-a possible common mechanism for some neurodegenerative diseases. But most proteinopathies are "sporadic," without gene mutation or overexpression. Thus, proteinopathies in wild-type animals genetically close to humans might be informative. Squirrel monkeys infected with classical bovine spongiform encephalopathy agent developed an encephalopathy resembling variant Creutzfeldt-Jakob disease with accumulations not only of abnormal prion protein (PrP(TSE)) but also three other proteins: hyperphosphorylated tau (p-tau), α-synuclein and ubiquitin; beta amyloid protein (Aβ) did not accumulate. Severity of brain lesions correlated with spongiform degeneration. No amyloid was detected. These results suggest that PrP(TSE) enhanced formation of p-tau and aggregation of α-synuclein and ubiquitin but not Aβ, providing a new experimental model for neurodegenerative diseases associated with complex proteinopathies.
    Journal of General Virology 04/2014; 95(Pt_7). DOI:10.1099/vir.0.062083-0 · 3.53 Impact Factor